Crossject : Une levée de fonds pour préparer l’approbation de Zepizure espérée au T1 25
>Augmentation de capital de 8 M€ avec une décote de 10% - Crossject annonçait mardi soir le lancement d’une augmentation de capital pour un montant de 8 M€. Cette opération est sécurisée par l’intermédiaire de son actionnaire historique Gemme Venture. En effet, ces derniers s’engagent à souscrire à minima pour 1,96 M€ (24,5% de l’AK) et garantissent un montant total de 6 M€ c’est-à-dire 75% de la levée.Le prix de souscription est de 1,848 € ce qui correspond à un...Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject's first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.